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Background: Schistosomiasis is a major cause of morbidity and mortality, with over 200 million people infected
worldwide. Eighty-five percent of cases are in Africa. The hepatosplenic form develops over time by an immune
reaction to trapped Schistosoma mansoni eggs in the portal system leading to liver fibrosis, portal hypertension and
oesophageal varices. Most patients presenting to the University Teaching Hospital in Lusaka with oesophageal
varices, come from Western province, but no formal studies have been carried out in this area assessing the burden
of hepatosplenic pathology. We aimed to define the extent of the problem in Kaoma district, western Zambia, and
to correlate signs and symptoms with serology.
Findings: A symptom questionnaire, demographic survey and physical examination was conducted amongst
patients presenting to Kaoma district outpatient clinics. To assess the prevalence of Schistosoma mansoni infections,
blood was collected and screened for the presence of Schistosoma antibodies using Enzyme linked immunosorbent
assay (ELISA). Of the 110 patients screened, 97 (88%) were ELISA positive. Forty-six percent (51/110) reported
haematochezia and 7% experienced haematemesis (8/110). On physical examination 27% (30/110) hepatomegaly
and 17% (30/110) splenomegaly was observed amongst participants but there were few correlations between
serology and signs/symptoms. On questioning 68% (75/110) of participants knew nothing about schistosomiasis
transmission.
Conclusions: Our serological and clinical data indicate a very heavy burden of schistosomiasis-related portal
hypertension. Our evidence highlights a need for mass treatment in Kaoma to address and prevent extensive
pathology of hepatosplenic schistosomiasis. Safe water and health education throughout Western Province are
clearly also important.
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Background
Schistosomiasis is a chronic parasitic disease causing
morbidity and mortality in over 200 million people
worldwide. Eighty-five percent of cases are in Africa [1].
Fifty-four million infections and over 130,000 deaths are
attributable to Schistosoma mansoni annually [2,3]. Zambia
has a population of approximately 13 million, 2 million
of which have schistosomiasis [4]. The prevalence of S.
mansoni is highest in some rural communities where* Correspondence: larapayne@doctors.org.uk
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reproduction in any medium, provided the oraccess to safe water and basic sanitation is limited [5]. Most
infections are asymptomatic or cause mild symptoms
such as diarrhoea and abdominal pains. However, 5-15%
of those infected with S. mansoni develop severe hepato-
splenic disease [6] characterized by hepatic fibrosis, hepato-
splenomegaly and portal hypertension [7,8].
The endoscopy unit in the University Teaching Hospital,
Lusaka serves the whole country. In an audit over five
years, it was observed that oesophageal varices are the most
common cause of gastrointestinal bleeding in Zambian
adults [9]. A high proportion of these patients were
noted to come from Kaoma district, Western Province
(Latitude:-14.8000; Longitude:24.8000). A subsequent survey
[10] found 8% of all adults in Kaoma had a lifetime historytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mansoni ova in stool samples, by the Kato-Katz technique,
which has high specificity but low sensitivity [11]. Although
surveys of schistosomiasis have indicated the disease is
endemic, surveillance and mass drug administration
(MDA) is focused at school-aged children and prevalence
in adults is often unknown [12]. At the time of our study
there was no documentation of MDA in the area and no
safe water issues were being addressed. The Schistosomiasis
Control Initiative plans prevalence studies and mass drug
administration in this area, but their initiatives will not
cover large scale ELISA testing. We used ELISA testing
for the presence of Schistosoma antibodies in serum, which
is the most sensitive method for assessing prevalence of in-
fection [13,14]. We thought it important to highlight the
extremely high seroprevalence and hepatosplenic disease
observed in the adult population in the hope that public
health initiatives could be expanded accordingly.
Methods
We carried out a cross-sectional study among adults
attending three out-patient departments of local health
centres in the region: Nyango clinic, Luampa and
Mangango hospitals. The first 110 patients presenting at
these facilities over three days in August 2011 were
recruited. The study population was restricted to those
aged 18 years or over who had resided in Kaoma district
for at least six months. All consecutive patients who met
the criteria and who agreed to participate were admitted
into the study irrespective of their initial presenting com-
plaint to the general outpatient clinic.
Ethics approval was obtained from the University of
Zambia Biomedical Research Ethics committee (Reference
number 010-07-11). Formal permission was granted by
the Ministry of Health and the Kaoma District Medical
Office. Information regarding the study was explained to
prospective study participants in their local language and
voluntary informed consent obtained. No payment was
made to test subjects but Praziquantel (a single dose of
40 mg/kg body weight) the standard treatment for
schistosomiasis in Zambia was arranged for individuals
who are found to be sero-positive for Schistosoma
antibodies.
Sample size was calculated as previous work suggests
that 10% of adult may have active schistosomiasis-related
portal hypertension (8% of those interviewed reporting
haematemesis [10]) and 86 samples will discriminate
between a prevalence of 10% and 20%, with a power of
80% at a confidence level of 95%. In fact 112 participants
were included and only two participants were subsequently
excluded as they had not lived in the study area for the
6 months required. No samples were lost.
The presence of antibodies to S. mansoni was detected
in participant’s serum using ELISA (Schisto 96, SciMedx,Denville, NJ). Positive samples were recorded according
to the anonymous patient identifier code. Positive and
negative standard control samples were run with each
kit to ensure accuracy. Results were analysed using a
spectrophotometer.
A questionnaire was administered by a local nurse/
clinical officer in the language of the respondent. The
participant was asked about symptoms of hepatosplenic
disease (blood in stool and haematemesis), stream contact,
history of previous infections and the treatment received.
A physical examination was performed to evaluate for
external signs of schistosomiasis. Community awareness
and understanding of schistosomiasis was also assessed
to see if further health education might be required.
Results were analysed with STATA™(Version 11.1) using
a two-sided Fisher’s exact test for correlation between those
who had a positive ELISA test against symptoms and risk
factors.
Results
The patients we recruited ranged from 18 to 89 years,
with 43 men and 67 women. There were 36 patients
from Mangango clinic, 27 from Nyango clinic
(encompassing the Luena streams) and 47 from Luampa
Hospital (catchment for the Luampa streams). There was
no previous recorded mass drug administration in this
area.
Of the 110 people tested, 97 (88%) were positive by
ELISA for Schistosoma antibodies. Only 49% (54/110)
reported previous schistosomiasis and 46% (51/110) of
respondents said they had been treated.
On questioning with regards to symptoms, 7%
reported haematemesis and 46% experienced blood in
stool. All participants with previous haematemesis were
positive for Schistosoma antibodies on ELISA. Twenty-
seven percent showed hepatomegaly, 17% splenomegaly,
and 72% pallor on examination. None of these signs or
symptoms except pallor showed significant correlation
with ELISA result but the majority of patients with these
hepatosplenic symptoms of pathology were positive by
ELISA (Table 1).
Socio-demographics were not predictive of schisto-
somiasis infection. Neither sex (p = 0.56) or age of par-
ticipants (p = 0.17) was significantly associated with
ELISA result. Sixty-four percent of respondents had
daily stream contact with either Luampa or Luena streams,
although this showed no correlation with ELISA result
(0.97, p = 1.00). The prevalence of Schistosoma anti-
bodies in the blood of the population served by the
Luampa streams was lower at 79% while the prevalence
of those in the Luena catchment averaged 95%. Com-
munity awareness and understanding of schistosomia-
sis was poor; 75 (68%) of participants could not tell us
anything about the transmission of schistosomiasis.




Elisa negative n (%)
Schistosoma
Elisa positive n (%)
P value
(2 sided Fisher’s Exact)
Total number of
participants with symptoms
Pallor 13 (17) 65 (83) 0.0100 78
Hepatomegaly 6 (21) 22 (79) 0.0901 28
Splenomegaly 4 (21) 15 (79) 0.2338 19
Blood in stool 4 (8) 46 (92) 0.3755 50
Haematemesis 0 8 (100) 0.5924 8
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Although studies and national prevalence surveys of schis-
tosomiasis have indicated that the disease is endemic in
most parts of Zambia, the actual prevalence of the disease
in adults is not known. The prevalence of hepatosplenic
schistosomiasis disease is also unknown although estimates
from a small survey based on questionnaires showed
that at least 8% of people with S. mansoni have severe
hepatosplenic disease [10]. We were concerned by reports
of a high burden of oesophageal varices reported from
Kaoma in Zambia. It was suspected that this could be
attributable to S. mansoni but there had been no previous
survey of this region.
We conducted a cross-sectional study involving a
symptom questionnaire, demographic survey and physical
examination amongst patients presenting to Kaoma out-
patient clinics to observe evidence of hepatosplenic disease.
To assess prevalence, blood collected was measured for
Schistosoma antibodies using ELISA.
Our study was the first to determine the seroprevalence
of infection along with patient awareness and hepatosplenic
disease in adults in the Kaoma region of Zambia. Other
studies have described endemic areas of schistosomiasis
using multiple methods for diagnosis which although is
more accurate it requires a high level of expertise and
takes a long time [15]. We hoped for a fast turnaround of
results so these could be implemented on in good time
given the scale of the problem in Kaoma.
Since doing this study diagnostics have improved for
S. mansoni with rapid diagnotic tests becoming available
[16] and circulating-urine cathodic antigen being widely
used in the field [17,18]. This study provided baseline
information upon which PhD research work was planned
and is underway to include a larger sample size and testing
participants with parasitological methods along with ELISA
and circulating-cathodic antigen for diagnosis.
We report very high prevalence of Schistosoma mansoni
in a part of Western Province, Zambia, where fishing is
the dominant way of life. From 110 participants, 88% were
ELISA positive. However, only 49% recalled prior infection,
indicating under-diagnosis. In the 46% of respondents who
said they had been treated, there was wide variation in the
treatment offered. Worryingly, 7% experienced haematem-
esis, a symptom of severe hepatosplenic pathology. Withregards to hepatosplenic signs 27% of participants showed
hepatomegaly, 17% had splenomegaly and 46% were
symptomatic, with blood in stool.
As well as in symptomatic individuals, there was a
high seroprevalance rate in those who were without
hepatosplenic symptoms but this is to be expected.
Typically the early stages of infection are asymptomatic.
The high prevalence rate and the expectation that not all
participants will have developed the signs or symptoms of
late hepatosplenic disease means it is difficult to draw
significant conclusions from the data obtained as although
the majority of those who had symptoms were positive by
ELISA that was also true of patients with no symptoms.
The only sign that was significant for those positive by
ELISA was pallor (Table 1), although non-specific this is
worth noting for clinicians in endemic areas as combined
with an appropriate history this could be the only sign of
early schistosomiasis.
Of course, the signs and symptoms illicited are potentially
attributable to multiple causes. But given the extremely
high seroprevalence of Schistosoma antibodies, we assume
that the majority of these late signs and symptoms of
hepatosplenic pathology when found in combination are
attributable to S. mansoni infection. Unfortunately the
ELISA positivity could represent past exposure or ongoing
infection with any Schistosoma species. Serological tests
available at the time did not distinguish between different
species of schistosome so it remains possible that some
positive serological results may have been due to S.
haematobium. Although this infection is common in
some parts of Zambia, local laboratory data and a recent
survey using urine filtration failed to detect any urinary
schistosomiasis in the Kaoma area. Recently, a study by
Lodh et al. was able to isolate and amplify S. mansoni spe-
cific DNA in urine samples collected from individuals
resident in this area further confirming previous work that
the area is predominately S. mansoni endemic [19]. A pre-
vious survey showed many positive stool samples [10],
indicating a high proportion of these patients were likely
to have S. mansoni exposure further supporting that our
data reflects a true mansoni prevalence.
Another limitation of this study includes our sample
being restricted to patients recruited in one of three
medical centres of Kaoma. There may have been a
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needed medical attention or a bias against those too un-
well to travel from their homes. Therefore we cannot be
sure that our data are representative of the general
population.
Our study provides evidence for mass drug adminis-
tration with praziquantel in the area as per Ministry of
Health policy in hyper-endemic areas (that have over
60% prevalence of schistosomiasis). Major interventions
to ensure safe water sources must be prioritized as the
majority (64%) of Kaoma inhabitants have daily contact
with contaminated streams. Health education is also cru-
cial as the majority (68%) of participants could not tell
us anything about the transmission of schistosomiasis.
The high burden of hepatosplenic pathology certainly
demonstrates the importance of improved health ser-
vices in Kaoma district and prompt referral to tertiary
care. Serious consideration should be given to provision of
a Provincial endoscopy service, with variceal ligation
and beta-blockade as therapeutic responses. A well-
supported ultrasonography service would also help find
patients at risk of developing oesophageal varices.
Conclusions
Our efforts highlight an extremely high seroprevalence
of schistosomiasis in this district with a high burden of
undiagnosed hepatosplenic disease. Our evidence high-
lights the need for continuing surveillance and regular
mass drug administration in line with Zambian Ministry
of Health policy in hyper-endemic regions. Major inter-
ventions are required to reduce the burden of disease in
this hyper-endemic community.
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